New drug shows promise for Hard-to-Treat cancers with p53 gene
NCT ID NCT02264613
First seen Jan 14, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This study tested a new drug, ALRN-6924, in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments. The study found the drug's safety and best dose, but it is not a cure and ongoing management is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Birmingham, Alabama, 35294, United States
-
Study site
Duarte, California, 91010, United States
-
Study site
Denver, Colorado, 80218, United States
-
Study site
Sarasota, Florida, 34232, United States
-
Study site
Tampa, Florida, 33612, United States
-
Study site
Boston, Massachusetts, 02114, United States
-
Study site
Boston, Massachusetts, 02215, United States
-
Study site
New York, New York, 10065, United States
-
Study site
The Bronx, New York, 10461, United States
-
Study site
Greenville, South Carolina, 29605, United States
-
Study site
Nashville, Tennessee, 37203, United States
-
Study site
Houston, Texas, 77030, United States
-
Study site
Seattle, Washington, 98105, United States
Conditions
Explore the condition pages connected to this study.